Neurocrine/NBIX

0.26%
-
1D1W1MYTD1YMAX

About Neurocrine

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.

Ticker

NBIX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kevin Gorman

Employees

1,448

Headquarters

San diego, United States

Neurocrine Metrics

BasicAdvanced
US$14B
Market cap
39.10
P/E ratio
US$3.64
EPS
0.37
Beta
-
Dividend rate
US$14B
0.36698
US$148.37
US$89.04
845K
2.524
2.471
5.146
36.633
12.68%
18.16%
15.58%
39.099
7.225
5.999
6.089
23.307
23.99%
496.52%
21.74%
-15.96%

What the Analysts think about Neurocrine

Analyst Ratings

Majority rating from 29 analysts.
Buy

Price Targets

Average projection from 25 analysts.
11.46% upside
High US$216.00
Low US$111.00
US$142.29
Current price
US$158.60
Average price target

Neurocrine Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
8.42% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$515M
0.02%
Net income
US$43M
-70.62%
Profit margin
8.42%
-70.62%

Neurocrine Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 58.35%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
US$0.95
US$0.82
US$1.44
US$0.42
-
Expected
US$0.78
US$0.97
US$1.15
US$1.01
US$1.03
Surprise
22.24%
-15.12%
25.75%
-58.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Neurocrine stock?

Neurocrine (NBIX) has a market cap of $14B as of May 20, 2024.

What is the P/E ratio for Neurocrine stock?

The price to earnings (P/E) ratio for Neurocrine (NBIX) stock is 39.1 as of May 20, 2024.

Does Neurocrine stock pay dividends?

No, Neurocrine (NBIX) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Neurocrine dividend payment date?

Neurocrine (NBIX) stock does not pay dividends to its shareholders.

What is the beta indicator for Neurocrine?

Neurocrine (NBIX) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Neurocrine stock price target?

The target price for Neurocrine (NBIX) stock is $158.6, which is 11.97% above the current price of $141.65. This is an average based on projections from 25 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Neurocrine stock

Buy or sell Neurocrine stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing